Profile data is unavailable for this security.
About the company
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.
- Revenue in USD (TTM)10.87m
- Net income in USD-228.68m
- Incorporated2012
- Employees253.00
- LocationAvidity Biosciences Inc10578 SCIENCE CENTER DRIVE, SUITE 125SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 401-7900
- Fax+1 (302) 636-5454
- Websitehttps://www.aviditybiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunocore Holdings PLC - ADR | 265.83m | -59.44m | 2.32bn | 497.00 | -- | 6.40 | -- | 8.71 | -1.20 | -1.20 | 5.27 | 7.23 | 0.3486 | 0.406 | 5.60 | 534,860.40 | -7.80 | -27.55 | -9.40 | -36.82 | 99.60 | -- | -22.36 | -97.12 | 5.94 | -- | 0.5489 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Vericel Corp | 207.78m | 451.00k | 2.33bn | 314.00 | 5,017.78 | 9.94 | 431.75 | 11.22 | 0.0096 | 0.0096 | 4.35 | 4.82 | 0.6684 | 4.38 | 4.71 | 661,719.80 | 0.1451 | -3.07 | 0.1621 | -3.50 | 69.50 | 67.87 | 0.2171 | -4.49 | 4.83 | -- | 0.0007 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.33bn | 160.00 | -- | 2.78 | -- | 384.04 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Novocure Ltd | 525.66m | -192.74m | 2.40bn | 1.45k | -- | 6.68 | -- | 4.57 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Arvinas Inc | 71.30m | -354.80m | 2.41bn | 445.00 | -- | 3.95 | -- | 33.83 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Janux Therapeutics Inc | 7.29m | -55.59m | 2.45bn | 64.00 | -- | 3.74 | -- | 336.28 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Twist Bioscience Corp | 277.49m | -192.14m | 2.47bn | 919.00 | -- | 4.41 | -- | 8.91 | -3.35 | -3.35 | 4.83 | 9.63 | 0.3565 | 4.87 | 7.04 | 301,943.40 | -24.68 | -30.50 | -27.12 | -33.84 | 38.29 | 36.02 | -69.24 | -113.33 | 5.06 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| ACADIA Pharmaceuticals Inc | 813.81m | -1.71m | 2.49bn | 610.00 | -- | 5.36 | 278.75 | 3.06 | -0.0129 | -0.0129 | 4.93 | 2.81 | 1.08 | 1.85 | 10.13 | 1,363,159.00 | -0.2264 | -27.50 | -0.3579 | -32.73 | 92.27 | 95.62 | -0.2101 | -38.35 | 1.86 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| Avidity Biosciences Inc | 10.87m | -228.68m | 2.52bn | 253.00 | -- | 3.03 | -- | 231.57 | -2.95 | -2.95 | 0.1408 | 8.69 | 0.0139 | -- | -- | 42,964.43 | -29.22 | -31.61 | -31.71 | -34.45 | -- | -- | -2,103.78 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
| TG Therapeutics Inc | 289.33m | 41.20m | 2.60bn | 284.00 | 76.42 | 16.27 | 62.95 | 9.00 | 0.2205 | 0.2205 | 1.97 | 1.04 | 1.01 | 0.3567 | 7.86 | 1,095,962.00 | 14.44 | -62.87 | 20.20 | -80.06 | 93.53 | -- | 14.24 | -405.03 | 2.84 | 4.01 | 0.3876 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| MoonLake Immunotherapeutics | 0.00 | -40.68m | 2.66bn | 50.00 | -- | 4.83 | -- | -- | -0.7501 | -0.7501 | 0.00 | 8.63 | 0.00 | -- | -- | 0.00 | -14.53 | -- | -15.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Denali Therapeutics Inc | 295.39m | -137.25m | 2.70bn | 375.00 | -- | 1.85 | -- | 9.12 | -0.9661 | -0.9661 | 2.09 | 10.21 | 0.1976 | -- | -- | 663,797.80 | -9.18 | -14.98 | -10.91 | -17.71 | -- | -- | -46.46 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Iovance Biotherapeutics Inc | 1.90m | -449.64m | 2.71bn | 557.00 | -- | 3.99 | -- | 1,425.62 | -1.82 | -1.82 | 0.0077 | 2.43 | 0.0023 | -- | -- | 3,418.31 | -53.07 | -51.47 | -59.00 | -57.56 | -846.22 | -- | -23,615.70 | -137,873.80 | 4.42 | -- | 0.0015 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 2.72bn | 570.00 | -- | 6.61 | -- | 9.91 | -0.9917 | -0.9917 | 2.08 | 1.63 | 0.1458 | 2.93 | 5.90 | 421,690.80 | -8.49 | 12.67 | -11.29 | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | 10.47 | -2.02 | 0.4169 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| 10X Genomics Inc | 625.45m | -264.30m | 2.72bn | 1.26k | -- | 3.78 | -- | 4.34 | -2.24 | -2.24 | 5.30 | 6.01 | 0.6458 | 2.67 | 7.39 | 496,781.60 | -27.29 | -25.52 | -30.80 | -29.05 | 64.62 | 75.88 | -42.26 | -48.53 | 4.45 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| Arcellx Inc | 131.66m | -50.54m | 2.74bn | 130.00 | -- | 5.51 | -- | 20.85 | -1.04 | -1.04 | 2.66 | 9.32 | 0.1877 | -- | -- | 1,012,792.00 | -7.21 | -38.82 | -8.96 | -45.41 | -- | -- | -38.39 | -339.38 | -- | -- | 0.0615 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
Data as of May 28 2024. Currency figures normalised to Avidity Biosciences Inc's reporting currency: US Dollar USD
75.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 13.57m | 17.03% |
| RTW Investments LPas of 31 Mar 2024 | 7.97m | 10.00% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 7.30m | 9.15% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 5.83m | 7.31% |
| Cowen & Co. LLCas of 31 Mar 2024 | 5.63m | 7.06% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.47m | 6.86% |
| RA Capital Management LPas of 26 Apr 2024 | 4.90m | 6.14% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.74m | 4.69% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.46m | 4.34% |
| Adage Capital Management LPas of 31 Mar 2024 | 2.40m | 3.01% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
